Analysts predict VK2735 could revolutionize the weight-loss ...

Moomoo AI Mar 27, 2024 22:16

Analysts predict VK2735 could revolutionize the weight-loss market with its oral administration. Truist maintains a buy rating, praising VK2735's top-tier status. William Blair sees potential for market expansion, impressed by the drug's safety profile. Oppenheimer sees VK2735 as a potential best-in-class due to its efficacy/safety profile.

Viking Therapeutics' Positive Results for Oral Weight-loss Drug Has Analysts Backing Buy Ratings

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

35K Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4873

Followers

Following

11K

Visitors